Growth signals CG Life, a pharma-focused advertising services agency with 201-500 employees and $100M-$250M in revenue, has been expanding its executive team in 2024 and 2026, indicating a readiness to scale client engagements and pursue larger, more complex rare-disease launches.

Strategic acquisitions The acquisition of Berry & Company Public Relations and the formation of a strategic communications group suggest opportunities to cross-sell expanded PR and integrated communications services to biopharma clients seeking comprehensive launch and market-facing capabilities.

Leadership depth Recent hires across C-suite and senior VP roles (CSO, CCO, CFO, SVP) point to a strengthened focus on strategy, client leadership, and financial discipline, enabling higher-value engagements with biotech firms navigating rare-disease commercialization.

Market focus CG Life positions itself around rare and hard-to-treat disease therapies, indicating recurring opportunities with biotech and specialty pharma companies that require science-driven, physician- and patient-community activation for successful market access.

Expansion readiness With a revenue band of $100M-$250M and notable hiring activity, CG Life appears equipped to pursue mid- to large-scale launches, suggesting potential upsell of strategic consulting, medical affairs support, and end-to-end commercial readiness services to existing and prospective clients.